IDYA vs IMVT Stock Comparison
IDYA currently leads IMVT in this stock comparison, with AIQ scores of 54 vs 52. The clearest difference is quality.
What is the main difference between IDYA and IMVT?
IDYA leads the current stock comparison as IDEAYA Biosciences, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
IDEAYA Biosciences, Inc. vs Immunovant, Inc.
IDYA leads
IDYA leads by 2 AIQ points, primarily on Quality and Risk Resilience, but the lead has narrowed from 14 points over 30 sessions.
Fragile: 2 of 4 evidence groups support IDYA, its lead is narrowing, and its signal state is cleanly positive.
IDEAYA Biosciences, Inc.
Immunovant, Inc.
The Algovestiq AIQ Score currently favors IDYA over IMVT, 54 versus 52 as of Nov 15, 2026. IDYA's advantage is driven primarily by stronger quality and risk resilience. IDYA also shows the weaker technical structure relative to its 50-day moving average. 2 of 4 covered evidence groups favor IDYA today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 2 points. IDYA lead: Weakening — the AIQ differential moved from 14 to 2 points over 30 sessions.
Compare IDEAYA Biosciences, Inc. and Immunovant, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare IDYA and IMVT against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality51 vs 42IDYA +9
- Risk Resilience61 vs 52IDYA +9
- Momentum63 vs 61Even
2 of 4 evidence groups favor IDYA. IDYA’s edge is concentrated in quality and risk resilience.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Value +2, not enough on its own to move the overall score.
New signals
- ADX Trend Strengthening — neutral, trend, medium horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-3.1%)
Largest factor move: Momentum +3
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.60x)
IDYA's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — IDYA and IMVT both carry a full feed there.
The central trade-off
IDYA (IDEAYA Biosciences, Inc.): the stronger current systematic profile, led by quality and risk resilience.
IMVT (Immunovant, Inc.): the counter-case, on technicals — but at materially higher volatility, 72.6% against 48.2%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
IDYAIDYA on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
IDYAIDYA on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
IDYAIDYA on Risk Resilience, by 9 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | IDYA | IMVT | Note |
|---|---|---|---|
| Implied upside to target | +53.2% | — | Level |
| Target dispersion | +36.9% | — | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 16 | 17 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 4 covered evidence groups favor IDYA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 54 vs 52 |
| Fundamentals | IDYA | revenue growth 15.6% vs -100%; TTM ROE -11.5% vs -14.8%; gross margin 100% vs 100%; operating margin -12.7% vs -74.9% |
| Valuation | Not covered | Not covered |
| Technicals | IMVT | Price vs 50-day -10.3% vs 4.7%; vs 200-day -6% vs 5.7% |
| Risk Resilience | IDYA | Risk Resilience 61 vs 52 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of IDYA and IMVT and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 2 points. (argues the conclusion is provisional)
- Only 2 of 4 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on IDYA.
How the comparison changed
120 daily snapshots · May 27 – Nov 13IDYA lead: Weakening — the AIQ differential moved from 14 to 2 points over 30 sessions.
- Today
- IDYA +2
- 54 vs 52
- 7 sessions ago
- IDYA +5
- 54 vs 49
- 30 sessions ago
- IDYA +14
- 63 vs 49
- 90 sessions ago
- IMVT +1
- 65 vs 66
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 0 bearish / 2 neutral
Only IDYA
- ADX Trend Strengthening — neutral, trend, medium horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-3.1%)
- RSI Bullish Divergence — bullish, momentum, medium horizon
4 bullish / 3 bearish / 1 neutral, conflicted
Only IMVT
- Beta Spike Warning — bearish, risk_regime, long horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.60x)
- RSI Bearish Divergence — bearish, momentum, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.
IMVT is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.08%, AIQ 0 points).
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.48%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1IMVT closes the Quality gap — currently 9 points behind, the largest single contributor to IDYA's edge.
- 2IMVT's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3IDYA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4The narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 2-point move would eliminate IDYA's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
IDYA leads on balance| Metric | IDYA | IMVT |
|---|---|---|
| Revenue growth (YoY) | 15.6% | -100% |
| EPS growth (YoY) | 0% | 37.3% |
| Gross margin | 100% | 100% |
| Operating margin | -12.7% | -74.9% |
| Return on equity (TTM) | -11.5% | -14.8% |
| Debt to equity | 0.03 | 0 |
Performance
IMVT leads 5 of 6 windows| Metric | IDYA | IMVT |
|---|---|---|
| 1 week (5 sessions) | 1.9% | 12% |
| 1 month (20 sessions) | -3.1% | 27.9% |
| 3 months (63 sessions) | -12.9% | -21.8% |
| 6 months (126 sessions) | 12.8% | 24.3% |
| Year to date | -7.9% | 34.5% |
| 1 year (252 sessions) | -0.4% | 45.8% |
Technicals
IMVT has the stronger structure| Metric | IDYA | IMVT |
|---|---|---|
| RSI (14) | 42.4 | 58.1 |
| ADX (14) | 25.8 | 33.1 |
| Price vs 50-day | -10.3% | 4.7% |
| Price vs 200-day | -6% | 5.7% |
| Volatility (1M, annualized) | 48.2% | 72.6% |
Risk
IDYA is the more resilient| Metric | IDYA | IMVT |
|---|---|---|
| Beta | 0.94 | 1.58 |
| Sharpe ratio | 0.14 | 0.9 |
| Sortino ratio | 0.2 | 1.77 |
| Max drawdown | -27.8% | -40.5% |
| Current drawdown | -25.1% | -24% |
| Annualized volatility | 44.9% | 58.6% |
| Value at risk (95%) | -4.1% | -4.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, IDYA or IMVT?
On the Algovestiq AIQ Score, IDYA is the stronger of the two as of Nov 15, 2026, scoring 54 against IMVT's 52. The edge comes from quality and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is IDYA or IMVT the better buy right now?
IDYA carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 2 points. Treat the lead as provisional.
Why does the AIQ Score favor IDYA over IMVT?
The composite weights Quality, Value, Momentum and Risk Resilience. IDYA leads Quality by 9 points; IDYA leads Risk Resilience by 9 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, IDYA or IMVT?
Analyst price targets imply +53.2% upside for IDYA and not covered for IMVT. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, IDYA or IMVT?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, IDYA or IMVT?
IDYA on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, IDYA or IMVT?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, IDYA or IMVT?
IDYA is the more resilient of the two, so the other name carries the higher downside risk. IDYA on Risk Resilience, by 9 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is IDYA more profitable than IMVT?
IDYA leads on the comparable margin measures — gross margin 100% vs 100%; operating margin -12.7% vs -74.9%; ttm roe -11.5% vs -14.8%.
Is IDYA's lead over IMVT getting stronger or weaker?
IDYA lead: Weakening — the AIQ differential moved from 14 to 2 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the IDYA vs IMVT verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: IMVT closes the Quality gap — currently 9 points behind, the largest single contributor to IDYA's edge; IMVT's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; IDYA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 2-point move would eliminate IDYA's advantage entirely.
What do the current signals say about IDYA and IMVT?
IDYA: 4 bullish / 0 bearish / 2 neutral. IMVT: 4 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on IDYA is Golden Cross Active (bullish, long horizon). On IMVT it is Golden Cross Active (bullish, long horizon).
Compare IDYA and IMVT with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.